体外受精卵巢刺激中联合来曲唑的影响:一项多中心、随机、双盲、安慰剂对照试验
这项多中心随机双盲安慰剂对照试验在丹麦四家大学医院生育门诊于2016年8月至2018年11月开展,纳入129例预期卵巢储备正常的女性,比较促性腺激素促排卵中联合来曲唑5 mg/天(n=67)与安慰剂(n=62)的效果。主要结局显示扳机日提前孕酮>1.5 ng/ml的比例两组无显著差异(6% vs 0%,OR 0.0,95%CI [0.0; 1.6],P=0.12),来曲唑组黄体中期孕酮>30 ng/ml比例显著升高(59% vs 31%,OR 3.3,95%CI [1.4; 7.1],P=0.005),持续妊娠率相似(31% vs 39%)。
要点
- 来曲唑联合治疗未显著改变扳机日提前孕酮>1.5 ng/ml的比例(6% vs 0%,OR 0.0,95%CI [0.0; 1.6],P=0.12)。
- 来曲唑组黄体中期孕酮>30 ng/ml比例显著高于安慰剂组(59% vs 31%,OR 3.3,95%CI [1.4; 7.1],P=0.005)。
- 来曲唑使扳机日雌二醇降低68%(95%CI [60%; 75%],P<0.0001),持续妊娠率两组相似(31% vs 39%)。
核心结论
- 来曲唑联合治疗对扳机日提前孕酮>1.5 ng/ml的主要结局无显著影响;来曲唑可能通过升高黄体中期孕酮优化黄体期内分泌,其对种植和持续妊娠率的影响需通过Meta分析或更大规模随机对照试验评估。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照试验,在丹麦四家大学医院生育门诊于2016年8月至2018年11月开展,129例预期卵巢储备正常(抗苗勒管激素8-32 nmol/l)的女性完成新鲜胚胎移植的IVF周期,来曲唑5 mg/天组n=67,安慰剂组n=62。
主要发现
- 扳机日提前孕酮>1.5 ng/ml的比例来曲唑组6% vs 安慰剂组0%(OR 0.0,95%CI [0.0; 1.6],P=0.12)。
- 黄体中期孕酮>30 ng/ml的比例来曲唑组59% vs 安慰剂组31%(OR 3.3,95%CI [1.4; 7.1],P=0.005)。
- 来曲唑组较安慰剂组扳机日雌二醇降低68%(95%CI [60%; 75%],P<0.0001)。
- 来曲唑组较安慰剂组卵泡期和黄体期LH分别增加38%(95%CI [21%; 58%],P<0.0001)和34%(95%CI [11%; 61%],P=0.006),睾酮分别增加79%(95%CI [55%; 105%],P<0.0001)和49%(95%CI [30%; 72%],P<0.0001),雄烯二酮分别增加85%(95%CI [59%; 114%],P<0.0001)和69%(95%CI [48%; 94%],P<0.0001)。
- 持续妊娠率来曲唑组31% vs 安慰剂组39%(风险差8%,95%CI [-25%; 11%],P=0.55),两组均无严重不良反应记录;外源性FSH刺激总时间来曲唑组缩短1天,总FSH消耗平均差-100 IU(95%CI [-192; -21],P=0.03)。
临床怎么用
- 作者认为来曲唑升高黄体中期孕酮可能有助于优化黄体期内分泌。
- 作者认为来曲唑升高雄激素和减少FSH消耗的作用可用于卵巢低反应者。
- 作者建议来曲唑对种植和持续妊娠率的影响应通过Meta分析或更大规模随机对照试验评估。
局限性
- 晚期卵泡期孕酮样本因患者后勤考虑在扳机前一天和扳机日采集,未考虑近期发现的孕酮昼夜节律变化。
- 研究把握度针对激素变化而非妊娠结局差异。
- 作者指出来曲唑对种植和持续妊娠率的影响应通过Meta分析或更大规模随机对照试验评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF reduce the proportion of women with premature progesterone levels above 1.5 ng/ml at the time of triggering final oocyte maturation? SUMMARY ANSWER: The proportion of women with premature progesterone above 1.5 ng/ml was not significantly affected by letrozole co-treatment. WHAT IS KNOWN ALREADY: IVF creates multiple follicles with supraphysiological levels of sex steroids interrupting the endocrine milieu and affects the window of implantation. Letrozole is an effective aromatase inhibitor, normalizing serum oestradiol, thereby ameliorating some of the detrimental effects of IVF treatment. STUDY DESIGN, SIZE, DURATION: A randomized, double-blinded placebo-controlled trial investigated letrozole intervention during stimulation for IVF with FSH. The trial was conducted at four fertility clinics at University Hospitals in Denmark from August 2016 to November 2018. PARTICIPANTS/MATERIALS, SETTING, METHODS: A cohort of 129 women with expected normal ovarian reserve (anti-Müllerian hormone 8-32 nmol/l) completed an IVF cycle with fresh embryo transfer and received co-treatment with either 5 mg/day letrozole (n = 67) or placebo (n = 62), along with the FSH. Progesterone, oestradiol, FSH, LH and androgens were analysed in repeated serum samples collected from the start of the stimulation to the mid-luteal phase. In addition, the effect of letrozole on reproductive outcomes, total FSH consumption and adverse events were assessed. MAIN RESULTS AND THE ROLE OF CHANCE: The proportion of women with premature progesterone >1.5 ng/ml was similar (6% vs 0% (OR 0.0, 95% CI [0.0; 1.6], P = 0.12) in the letrozole versus placebo groups, respectively), whereas the proportion of women with mid-luteal progesterone >30 ng/ml was significantly increased in the letrozole group: (59% vs 31% (OR 3.3, 95% CI [1.4; 7.1], P = 0.005)). Letrozole versus placebo decreased oestradiol levels on the ovulation trigger day by 68% (95% CI [60%; 75%], P < 0.0001). Other hormonal profiles, measured as AUC, showed the following results. The increase in LH in the letrozole group versus placebo group was 38% (95% CI [21%; 58%], P < 0.0001) and 34% (95% CI [11%; 61%], P = 0.006) in the follicular and luteal phases, respectively. In the letrozole group versus placebo group, testosterone increased by 79% (95% CI [55%; 105%], P < 0.0001) and 49% (95% CI [30%; 72%], P < 0.0001) in the follicular and luteal phases, respectively. In the letrozole group versus placebo group, the increase in androstenedione was by 85% (95% CI [59%; 114%], P < 0.0001) and 69% (95% CI [48%; 94%], P < 0.0001) in the follicular and luteal phases, respectively. The ongoing pregnancy rate was similar between the letrozole and placebo groups (31% vs 39% (risk-difference of 8%, 95% CI [-25%; 11%], P = 0.55)). No serious adverse reactions were recorded in either group. The total duration of exogenous FSH stimulation was 1 day shorter in the intervention group, significantly reducing total FSH consumption (mean difference -100 IU, 95% CI [-192; -21], P = 0.03). LIMITATIONS, REASONS FOR CAUTION: Late follicular progesterone samples were collected on the day before and day of ovulation triggering for patient logistic considerations, and the recently emerged knowledge about diurnal variation of progesterone was not taken into account. The study was powered to detect hormonal variations but not differences in pregnancy outcomes. WIDER IMPLICATIONS OF THE FINDINGS: Although the use of letrozole has no effect on the primary outcome, the number of women with a premature increase in progesterone on the day of ovulation triggering, the increased progesterone in the mid-luteal phase due to letrozole may contribute to optimizing the luteal phase endocrinology. The effect of letrozole on increasing androgens and reducing FSH consumption may be used in poor responders. However, the effect of letrozole on implantation and ongoing pregnancy rates should be evaluated in a meta-analysis or larger randomized controlled trial (RCT). STUDY FUNDING/COMPETING INTEREST(S): Funding was received from EU Interreg for ReproUnion and Ferring Pharmaceuticals, and Roche Diagnostics contributed with assays. N.S.M. and A.P. have received grants from Ferring, Merck Serono, Anecova and Gedeon Richter, and/or personal fees from IBSA, Vivoplex, ArtPred and SPD, outside the submitted work. The remaining authors have no competing interests. TRIAL REGISTRATION NUMBERS: NCT02939898 and NCT02946684. TRIAL REGISTRATION DATE: 15 August 2016. DATE OF FIRST PATIENT’S ENROLMENT: 22 August 2016.
引用
- Bülow NS, Skouby SO, Warzecha AK, et al. Impact of letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF: a multicentre, randomized, double-blinded placebo-controlled trial. Hum Reprod. 2022. PMID: 34792133. doi:10.1093/humrep/deab249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。